登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C9H9Cl2N3 · HCl
化学文摘社编号:
分子量:
266.55
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
224-121-5
MDL number:
Beilstein/REAXYS Number:
4163525
产品名称
可乐定 盐酸盐, solid
InChI key
ZNIFSRGNXRYGHF-UHFFFAOYSA-N
InChI
1S/C9H9Cl2N3.ClH/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9;/h1-3H,4-5H2,(H2,12,13,14);1H
SMILES string
Cl[H].Clc1cccc(Cl)c1NC2=NCCN2
form
solid
color
white
solubility
H2O: soluble
methanol: soluble
originator
Boehringer Ingelheim
storage temp.
2-8°C
Quality Level
Gene Information
human ... ADRA2A(150), ADRA2B(151), ADRA2C(152)
正在寻找类似产品? 访问 产品对比指南
Features and Benefits
该化合物由 Boehringer Ingelheim 开发。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单,请单击此处。
Application
可乐定盐酸盐已被用于:
- 降低中央去甲肾上腺素水平
- 抑制异硫氰酸烯丙酯(AITC)敏化的热厌恶
- 减轻大鼠的热和机械性疼痛超敏反应
- 作为百日咳毒素(PTX)的阳性对照
盐酸可乐定已作为肾上腺素能受体(ADRA2A)激动剂用于:
- 离体 瘦素释放测定
- 研究其对6-OHDA损伤大鼠疼痛超敏反应的影响
- 研究其对幼虫斑马鱼睡眠的影响
- 操纵去甲肾上腺素并检查其对行为灵活性和动机的影响
Biochem/physiol Actions
α2-肾上腺素能受体激动剂;I1 咪唑啉结合位点配体。
盐酸可乐定可用于治疗孕妇的高血压。此外,它还可以作为新生儿戒断综合征的治疗剂。盐酸可乐定可与α-肾上腺素能受体的中心结合,并降低心脏、肾脏和周围脉管系统的交感神经元血管收缩压,从而导致血管舒张和血压降低。
General description
盐酸可乐定具有降压、止痛和止泻特性。它在体外,可降低短路电流,阻止阴离子的分泌,并改善粘膜对液体和电解质的吸收。可乐定可用于治疗注意力不足和多动症(ADHD)、更年期潮红、撤药综合征和Tourette′s综合征。
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 1 Inhalation - Acute Tox. 3 Oral
存储类别
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges
Clonidine for smoking cessation
Gourlay SG, et al.
Cochrane database of systematic reviews (Online), 3, 105-105 (2004)
R M Eglen et al.
Trends in pharmacological sciences, 19(9), 381-390 (1998-10-24)
Although imidazoline sites have been the subject of research for several years, there is still controversy about their structure, diversity and physiology. The I1 site is thought to exist principally as a binding site and is widely purported to play
Clonidine hydrochloride--a safe and effective antihypertensive agent in pregnancy.
Horvath JS, et al.
Obstetrics and Gynecology, 66(5), 634-638 (1985)
Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders
Ming X, et al.
Adolescent health, medicine and therapeutics, 2(2), 105-105 (2011)
Clonidine hydrochloride: Review of pharmacologic and clinical aspects
Houston MC
Progress in Cardiovascular Diseases, 23(5), 337-350 (1981)
相关内容
Product Information Sheet
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持